Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast Cancer

NCT ID: NCT01077453

Last Updated: 2014-10-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 112 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-03-31

Brief Summary

This randomized phase I trial studies the side effects and the best dose of letrozole in preventing breast cancer in healthy postmenopausal women at high risk for breast cancer. Chemoprevention is the use of drugs to keep breast cancer from forming or coming back. The use of letrozole may keep cancer from forming in healthy postmenopausal women at high risk for breast cancer.

Detailed Description

PRIMARY OBJECTIVES:

I. Compare the effect of lower and intermittent doses of letrozole to standard letrozole therapy on estrogen suppression in postmenopausal women at high risk for developing breast cancer.

SECONDARY OBJECTIVES:

I. Comparison of the effect of lower and intermittent doses of letrozole to standard therapy on signs and symptoms of estrogen deficiency, including menopausal symptoms, serum lipid profile, and serum marker of bone turnover.

II. Comparison of the effect of lower and intermittent doses of letrozole to standard therapy on nuclear chromatin abnormality of breast epithelial cells collected by random periareolar fine needle aspiration (RPFNA).

TERTIARY OBJECTIVES:

I. Determine the prevalence of breast cancer stem cells in the fine needle breast aspirates and explore the potential intervention effect on the prevalence of breast cancer stem cells.

OUTLINE: Patients are randomized to 1 of 4 treatment arms.

ARM I: Patients receive 2.5 mg of letrozole orally (PO) thrice weekly for 6 months.

ARM II: Patients receive 1.0 mg of letrozole PO thrice weekly for 6 months.

ARM III: Patients receive 0.25 mg of letrozole PO thrice weekly for 6 months.

ARM IV: Patients receive 2.5 mg of letrozole PO once daily for 6 months.

After completion of study treatment, patients are followed up at week 30.

Conditions

Healthy, no Evidence of Disease; Lobular Breast Carcinoma in Situ

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: DOUBLE

Study Groups

Arm I (2.5 mg letrozole)

Patients receive 2.5 mg of letrozole PO thrice weekly for 6 months.

Group Type: EXPERIMENTAL

letrozole

Intervention Type: DRUG

Given orally

quality-of-life assessment

Intervention Type: OTHER

Ancillary studies

laboratory biomarker analysis

Intervention Type: OTHER

Correlative studies

Arm II (1.0 mg letrozole)

Patients receive 1.0 mg of letrozole PO thrice weekly for 6 months.

Group Type: EXPERIMENTAL

letrozole

Intervention Type: DRUG

Given orally

quality-of-life assessment

Intervention Type: OTHER

Ancillary studies

laboratory biomarker analysis

Intervention Type: OTHER

Correlative studies

Arm III (0.25 mg letrozole)

Patients receive 0.25 mg of letrozole PO thrice weekly for 6 months.

Group Type: EXPERIMENTAL

letrozole

Intervention Type: DRUG

Given orally

quality-of-life assessment

Intervention Type: OTHER

Ancillary studies

laboratory biomarker analysis

Intervention Type: OTHER

Correlative studies

Arm IV (2.5 mg letrozole)

Patients receive 2.5 mg of letrozole PO once daily for 6 months.

Group Type: EXPERIMENTAL

letrozole

Intervention Type: DRUG

Given orally

quality-of-life assessment

Intervention Type: OTHER

Ancillary studies

laboratory biomarker analysis

Intervention Type: OTHER

Correlative studies

Interventions

letrozole

Given orally

Intervention Type: DRUG

quality-of-life assessment

Ancillary studies

Intervention Type: OTHER

laboratory biomarker analysis

Correlative studies

Intervention Type: OTHER

Other Intervention Names

CGS 20267; Femara; LTZ; quality of life assessment

Eligibility Criteria

Inclusion Criteria

• Healthy postmenopausal women at "high risk" for breast cancer will be eligible for the study; definition of menopause will be:

• Amenorrhea for at least 12 months, or
• History of hysterectomy and bilateral salpingo-oophorectomy, or
• At least 55 years of age with prior hysterectomy with or without oophorectomy, or
• Age 35 to 54 with a prior hysterectomy without oophorectomy OR with a status of ovaries unknown with documented follicle-stimulating hormone level demonstrating elevation in postmenopausal range
• "High risk" for breast cancer will be defined as:

• Prior histologically confirmed lobular carcinoma in situ (LCIS) treated by local excision only, or
• At least 1.66% probability of invasive breast cancer within 5 years using the Breast Cancer Risk Assessment Tool
• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1; Karnofsky 80% or above
• Leukocytes >= 3,000/uL
• Absolute neutrophil count >= 1,500/uL
• Platelets >= 100,000/uL
• Total bilirubin =< 2.0 mg/dL
• Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.0 X institutional ULN
• Creatinine =< 1 X institutional ULN
• Recent mammogram negative for breast cancer, Breast Imaging-Reporting and Data System (BIRADS) score < 3 (within the last 12 months)
• Ability to understand and the willingness to sign a written informed consent document; only potential participants with the ability to understand and the willingness to sign a written document will be presented with an informed consenting document

Exclusion Criteria

• Women diagnosed with osteoporosis (previously or on screening dual-energy X-ray absorptiometry [DEXA] for this study) and not on a stable dose of long or short-acting bisphosphonates therapy for at least 3 months will be excluded from the study; women diagnosed with osteoporosis and on raloxifene (Evista) therapy will be excluded from the study; use of calcium and/or vitamin D for osteoporosis prevention or treatment is allowed; women with osteopenia will be allowed to participate in this study
• Have had invasive cancer within the past five years except non-melanoma skin cancer
• Evidence of suspicious of malignant disease on bilateral mammogram within the past year unless ruled out by further evaluation
• History of prior invasive breast cancer or intraductal carcinoma in situ, or history of prior radiation therapy to the chest or breast
• Participants may not be receiving any other investigational agents; participants may not be concurrently enrolled in another breast cancer prevention intervention trial
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to letrozole
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• Within 3 months since prior estrogen or progesterone replacement therapy, oral contraceptives, androgens, luteinizing hormone-releasing hormone analogs, prolactin inhibitors, or antiandrogens
• Within 3 months since prior tamoxifen, raloxifene, or other selective estrogen-receptor modulators
• Within 3 months since regular use (more than 2 times a week) of prior estrogenic supplements or herbal remedies
• History of bleeding or clotting disorder; current or recent (within 3 months) use of Coumadin, Plavix or other systemic anticoagulant other than aspirin is not permitted if subject chooses to participate in the optional RPFNA procedure; if a subject chooses not to participate in the RPFNA procedure, prior or current treatment with systemic anticoagulants is permitted

• Minimum Eligible Age: 35 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ana Lopez

Role: PRINCIPAL_INVESTIGATOR

University of Arizona Health Sciences Center

Locations

Arizona Cancer Center - Tucson

Tucson, Arizona, United States

University of Arizona Health Sciences Center

Tucson, Arizona, United States

Mayo Clinic

Rochester, Minnesota, United States

Countries

United States

References

Lopez AM, Pruthi S, Boughey JC, Perloff M, Hsu CH, Lang JE, Ley M, Frank D, Taverna JA, Chow HH. Double-Blind, Randomized Trial of Alternative Letrozole Dosing Regimens in Postmenopausal Women with Increased Breast Cancer Risk. Cancer Prev Res (Phila). 2016 Feb;9(2):142-8. doi: 10.1158/1940-6207.CAPR-15-0322. Epub 2015 Dec 14.

Reference Type: DERIVED

PMID: 26667449 (View on PubMed)

Other Identifiers

NCI-2013-00757

Identifier Type: REGISTRY

Identifier Source: secondary_id

09-0869-04

Identifier Type: OTHER

Identifier Source: secondary_id

UAZ08-12-02

Identifier Type: OTHER

Identifier Source: secondary_id

N01CN35158

Identifier Type: NIH

Identifier Source: secondary_id

View Link

P30CA023074

Identifier Type: NIH

Identifier Source: secondary_id

View Link

NCI-2013-00757

Identifier Type: -

Identifier Source: org_study_id